| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target LM Walker, SK Phogat, PY Chan-Hui, D Wagner, P Phung, JL Goss, ... Science 326 (5950), 285-289, 2009 | 2087 | 2009 |
| Broad neutralization coverage of HIV by multiple highly potent antibodies LM Walker, M Huber, KJ Doores, E Falkowska, R Pejchal, JP Julien, ... Nature 477 (7365), 466-470, 2011 | 1728 | 2011 |
| PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma PT Nghiem, S Bhatia, EJ Lipson, RR Kudchadkar, NJ Miller, L Annamalai, ... New England Journal of Medicine 374 (26), 2542-2552, 2016 | 1272 | 2016 |
| Peptide and protein molecular weight determination by electrophoresis using a high-molarity tris buffer system without urea SP Fling, DS Gregerson Analytical biochemistry 155 (1), 83-88, 1986 | 1185 | 1986 |
| Gene expression markers of tumor infiltrating leukocytes P Danaher, S Warren, L Dennis, L D’Amico, A White, ML Disis, MA Geller, ... Journal for immunotherapy of cancer 5, 1-15, 2017 | 640 | 2017 |
| HLA-DMA and-DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells SP Fling, B Arp, D Pious Nature 368 (6471), 554-558, 1994 | 364 | 1994 |
| Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy P Nghiem, S Bhatia, EJ Lipson, WH Sharfman, RR Kudchadkar, AS Brohl, ... Journal of Clinical Oncology 37 (9), 693-702, 2019 | 358 | 2019 |
| A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease MM Fort, A Mozaffarian, AG Stöver, JS Correia, DA Johnson, RT Crane, ... The Journal of Immunology 174 (10), 6416-6423, 2005 | 284 | 2005 |
| Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study MS Khodadoust, AH Rook, P Porcu, F Foss, AJ Moskowitz, A Shustov, ... Journal of Clinical Oncology 38 (1), 20, 2020 | 189 | 2020 |
| Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer—a phase 1 study TS Uldrick, PH Gonçalves, M Abdul-Hay, AJ Claeys, B Emu, MS Ernstoff, ... JAMA oncology 5 (9), 1332-1339, 2019 | 185 | 2019 |
| CD8+ T cells recognize an inclusion membrane-associated protein from the vacuolar pathogen Chlamydia trachomatis SP Fling, RA Sutherland, LN Steele, B Hess, SEF D'Orazio, ... Proceedings of the National Academy of Sciences 98 (3), 1160-1165, 2001 | 178 | 2001 |
| Tuberculosis following PD-1 blockade for cancer immunotherapy DL Barber, S Sakai, RR Kudchadkar, SP Fling, TA Day, JA Vergara, ... Science translational medicine 11 (475), eaat2702, 2019 | 168 | 2019 |
| Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors K Margolin, C Morishima, V Velcheti, JS Miller, SM Lee, AW Silk, ... Clinical Cancer Research 24 (22), 5552-5561, 2018 | 168 | 2018 |
| Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis RN Coler, A Campos-Neto, P Ovendale, FH Day, SP Fling, L Zhu, ... The Journal of Immunology 166 (10), 6227-6235, 2001 | 144 | 2001 |
| An inclusion membrane protein from Chlamydia trachomatis enters the MHC class I pathway and stimulates a CD8+ T cell response MN Starnbach, WP Loomis, P Ovendale, D Regan, B Hess, MR Alderson, ... The Journal of Immunology 171 (9), 4742-4749, 2003 | 142 | 2003 |
| The murine cytomegalovirus immunomodulatory gene m152 prevents recognition of infected cells by M45-specific CTL but does not alter the immunodominance of the M45-specific CD8 … MC Gold, MW Munks, M Wagner, UH Koszinowski, AB Hill, SP Fling The Journal of Immunology 169 (1), 359-365, 2002 | 140 | 2002 |
| Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity DM Lewinsohn, L Zhu, VJ Madison, DC Dillon, SP Fling, SG Reed, ... The Journal of Immunology 166 (1), 439-446, 2001 | 133 | 2001 |
| S-antigen-specific rat T cell lines recognize peptide fragments of S-antigen and mediate experimental autoimmune uveoretinitis and pinealitis. DS Gregerson, WF Obritsch, SP Fling, JD Cameron Journal of immunology (Baltimore, Md.: 1950) 136 (8), 2875-2882, 1986 | 111 | 1986 |
| Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma D Phillips, M Matusiak, BR Gutierrez, SS Bhate, GL Barlow, S Jiang, ... Nature communications 12 (1), 6726, 2021 | 109 | 2021 |
| Pembrolizumab for treatment of relapsed/refractory mycosis fungoides and Sezary syndrome: clinical efficacy in a CITN multicenter phase 2 study M Khodadoust, AH Rook, P Porcu, FM Foss, AJ Moskowitz, AR Shustov, ... Blood 128 (22), 181, 2016 | 90 | 2016 |
